Lowering biotech venture risk through marginal cost structures
The speaker outlined an investment thesis focused on lowering the fixed costs of biotech venture investing by operating shared internal labs and leveraging genetics-based target validation.
Keep reading this one
You've read the thesis and who argued it. A free account opens the argument, what validates it, the risks the show raised, and the moment in the episode where it was said — 3 ideas in full a day, no card.